Bellinger Andrew 4
4 · Verve Therapeutics, Inc. · Filed Jul 22, 2022
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-07-20$1.39/sh+20,000$27,800→ 26,629 total - Exercise/Conversion
Stock Option (right to buy)
2022-07-20−20,000→ 1,599 totalExercise: $1.39Exp: 2029-06-24→ Common Stock (20,000 underlying) - Sale
Common Stock
2022-07-20$34.90/sh−20,000$698,000→ 6,629 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2022.
- [F2]The option was granted on June 25, 2019 for 21,599 shares. The shares underlying the option vested on May 1, 2020.